These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3742507)

  • 1. Hormone steroid receptor variation after tamoxifen administration in endometrial adenocarcinoma from postmenopausal patients.
    Di Fronzo G; Ronchi E; Cappelletti V; Luciani L; Coradini D; Oriana S; Miodini P; Andreola S
    Cancer Detect Prev; 1986; 9(3-4):323-30. PubMed ID: 3742507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of estrogen and progestin receptor concentrations in an experimental rat prostatic carcinoma by estrogen, antiestrogen, and progesterone.
    Mobbs BG; Johnson IE; DeSombre ER; Toth J; Hughes A
    Cancer Res; 1987 May; 47(10):2645-51. PubMed ID: 3552202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer.
    Lundgren S; Søreide JA; Lea OA
    Anticancer Res; 1994; 14(3B):1313-6. PubMed ID: 8067700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in receptor status after treatment with tamoxifen in endometrial cancer.
    Oriana S; Raspagliesi F; Duca PG; Coradini D; Di Re EM; Ragazzi D; Grillo T; Luciani L
    Int J Biol Markers; 1988; 3(4):233-6. PubMed ID: 3235850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced growth of an estrogen receptor-negative endometrial adenocarcinoma by estradiol in athymic mice.
    Friedl A; Gottardis MM; Pink J; Buchler DA; Jordan VC
    Cancer Res; 1989 Sep; 49(17):4758-64. PubMed ID: 2758409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of estrogen receptor, progesterone receptor, and the estrogen-regulated Mr 24,000 protein in patients with carcinomas of the endometrium and cervix.
    Ciocca DR; Puy LA; Fasoli LC
    Cancer Res; 1989 Aug; 49(15):4298-304. PubMed ID: 2743317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid receptor expression in endometria from women treated with tamoxifen.
    Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
    Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma.
    Vargas Roig LM; Lotfi H; Olcese JE; Lo Castro G; Ciocca DR
    Anticancer Res; 1993; 13(6B):2457-63. PubMed ID: 7907850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Histopathological changes in endometrial cancer treated with tamoxifen].
    Lin HH; Ueda K; Kato J
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1038-43. PubMed ID: 3963849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
    Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
    Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
    Calzada L; Salazar EL; Pedron Nuevo N
    Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels.
    Saez S; Martin PM; Chouvet CD
    Cancer Res; 1978 Oct; 38(10):3468-73. PubMed ID: 688231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice.
    Satyaswaroop PG; Zaino RJ; Mortel R
    Cancer Res; 1984 Sep; 44(9):4006-10. PubMed ID: 6744316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative oestrogen and progesterone receptor values in primary breast cancer and predictability of response to endocrine therapy.
    Fernandez MD; Alaghband-Zadeh J; Burn JI
    Clin Oncol; 1983 Sep; 9(3):245-50. PubMed ID: 6616999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.